GENE THERAPY

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

II. EXECUTIVE SUMMARY

1. Market Dynamics II-1

• Future - On a Promising Note II-1
• Market Predictions Thrive On II-1
• China - First to Hit the Market II-1
• Counting on the Success Factors II-1
• Global Market by Region II-2
• US-Largest Market... II-2
• Rest of World-Growing Rapidly... II-2

2. Key Issues/ Trends II-3

• Factors Influencing Gene Therapy Future Development II-3
• Human Genome Analysis II-3
• Diagnostic Industry Moves II-3
• Public Support for Gene Therapy II-3
• Factors Hampering Market Growth II-3
• Identifying Genetic Fault II-3
• Immune Response II-3
• Delivering Genetic Materials into Patient Cells II-3
• Multigene Disorders II-4
• Side Effects II-4
• Push Towards Germline Gene Transfer II-4

3. The Global Landscape II-5

• Alliances and Acquisitions - Strategy to Success II-5
• Companies and Partnerships II-5
• Patent Pooling: Yet Another Obstacle II-6
• Commercialization: A Road Uphill II-6
• Time Line in Gene Therapy Drug Development II-7
• Target Diseases and Players Involved II-7
• Key Players by Application Area II-7
• Table 1: Gene Therapy Clinical Trials Worldwide (2004): Percentage Breakdown by Disease/ Application Area for Cancer, Cystic Fibrosis, Heart Disease, HIV, and Others (Includes Corresponding Graph/Chart) II-8
• Table 2: Gene Therapy Clinical Trials Worldwide (2004): Percentage Breakdown by Gene Type Transferred for Cytokine, Antigen, Tumor Suppressor, Suicide, Deficiency, Drug Resistance, and Others (Includes Corresponding Graph/Chart) II-8
• Table 3: Gene Therapy Clinical Trials Worldwide (2004): A Split by Development Phase (Includes Corresponding Graph/Chart) II-8
• Table 4: Gene Therapy Clinical Trials (2004): Percentage Breakdown by Geographic Region for US, Canada, Japan, Europe and Rest of World (Includes Corresponding Graph/Chart) II-9
• Various Gene Therapy Products Under Development (2005) II-9
• Gene Therapy Industry in Europe and the US - A Comparison II-10

4. Gene Therapy - An Insight II-11

• Molecular Basics - The Gene II-11
• Genome - The Information Pool II-11
• Functional cloning II-11
• Random sequencing II-11
• Positional cloning. II-12
• What is Gene Therapy? II-12
• A Backdrop II-12
• 1990 Highlights - The Preliminary Gene Therapy Trial II-12
• 1995 Highlights II-12
• 2000 Highlights - Clinical Trials Reaches 400- Milestone II-12
• 2004 Witnesses the First Gene Therapy Drug II-13
• Classical Theory of Gene Therapy II-13
• Ex-Vivo Approach of Gene Therapy II-13
• In-vivo Approach of Gene Therapy II-13
• Types of Gene Therapy II-13
• Monogenic Gene Therapy II-13
• Suicide Gene Therapy II-14
• Antisense Gene Therapy II-14
• Various Approaches II-14

5. Components of Gene Therapy II-15

• Vector II-15
• Delivery Vehicles and Challenges in Use of Viral Vectors II-15
• Gene Delivery - Without Virus II-15
• Recent Release of Non-Viral Products II-16
• Well-known Delivery Approaches for Gene Therapy II-16
• Viral and Non-viral Vectors in Use II-17
• Retroviruses II-17
• Adenoviruses II-17
• Adenoassociated viruses II-17
• Herpes simplex viruses II-17
• Lentiviruses II-17
• Liposomes II-17
• Viral Vectors by Companies involved II-17
• Gene Cassette II-18
• Target cells II-18
• Stem cells II-18
• Differentiated cells II-18
• The Disc: An Excellent Target for Gene Therapy II-18

6. Review of Various Approaches II-19

• Antisense Technology II-19
• Catalytic Ribozyme Technology II-19
• Triple Helix DNA II-19

7. Gene Therapy For Disease Treatment II-21

• Gene Therapy - A Way to Fight or Cure Genetic Disease? II-21
• Gene Therapy for Cancer Treatment II-21
• Gene Transfer and Gene Therapeutic Concepts in Cancer II-21
• Competitive Landscape in Cancer Gene Therapy II-22
• Developments in Cancer Gene Therapy II-22
• P53 Gene Therapy - A Novel Approach in Cancer Treatment II-23
• p53 Cancer Gene Therapy Drugs in Development (2004) II-23
• Gendicine - From Concept to Reality II-24
• Vaccines II-24
• Cancer Treatment with Gene Therapy and Radiation Therapy II-24
• Gene Therapy for Cardiovascular Disease II-25
• Cardiovascular Gene Therapy Products under Trial II-25
• Gene Therapy for Cystic Fibrosis Disease II-25
• Gene Therapy for Haemophilia B II-26
• Companies Engaged in Developing Gene Therapy Drugs against Haemophilia II-26
• Gene Therapy for HIV/AIDS II-27
• Gene Therapy for Parkinson's Disease II-27
• The Disease II-27
• Therapy II-28

8. Regulatory Environment II-29

• Gene therapy and Regulatory Environment II-29
• Gene Patents - An Overview II-29
• Regulations Governing Gene Therapy by Region II-30
• The US II-30
• Food and Drug Administration (FDA) II-30
• FDA Requires Additional Toxicology and Biodistribution Studies II-30
• CBER II-31
• NIH II-31
• RAC II-31
• Role of NIH II-32
• IRB and IBC II-32
• Outline description of approval process of FDA and NIH II-33
• European Union II-33
• France II-34
• United Kingdom II-34
• Local Research Ethics Committee (LREC) II-34
• Medicines Control Agency II-34
• Germany II-34
• Switzerland II-35
• Austria II-35
• Italy II-35
• Sweden II-36
• The Netherlands II-36
• Belgium II-36
• Spain II-36
• Japan II-36

9. Research and Development II-37

• AMT Develops (AAV) Vector-Based Gene Therapy II-37
• Ark Comes Up with New Gene Thearpy Delivery Technology II-37
• Oxford University to Come Up with Gene Therapy for Hypertension II-37
• Asklepios to Develop New Gene Therapy II-37
• AGTC to Develop Gene Therapy for Heart Failure II-37

10. Recent Industry Activity II-38

• Diamyd Acquires Nurel II-38
• Oxford BioMedica Accords with Sigma-Alrdrich II-38
• Oxford BioMedica Inks Licensing Agreement with Pfizer II-38
• genOway Signs Two General Service Agreements II-38
• genOway Acquires IngenKO Pty Ltd II-38
• genOway Germany Participates in EU 6th Framework Program II-38
• Crucell Strikes a Deal with Two Asian Firms II-39
• Corautus' VEGF-2 Gene Therapy Gains Recognition from US FDA II-39
• ViroMed Ceases Development of Gene Therapy II-39
• Corautus Genetics Pacts with CSEMC II-39
• Takara Bio Collaborates with Mie University II-39
• Celladon Accords with V-Kardia II-39
• Genzyme Acquires Ilex Oncology II-39
• Genzyme and AGTC Form Collaboration II-40
• Sanofi-Synthelabo Merges with Aventis II-40
• Guidant Forms Collaboration with Columbia and Stony Brook II-40
• Avigen Concludes Collaboration with Bayer II-40
• Louisiana and Bionomics Team-Up II-40
• Avigen Receives FDA Clearance to Commence Phase I/II Clinical Trial of Av201 II-41
• Oxford BioMedica and Viragen Enters into Licensing Agreement II-41
• Oxford BioMedica Signs Licensing Agreement with Merck II-41
• Avigen Starts Gene Therapy Trial for Parkinson's Disease... II-41
• Oxford BioMedica Acquires Chiron Patents II-41
• UA duo Establishes Gene-therapy Firm II-41
• SiBiono Commences Construction of Gene Therapy Facility II-42
• Avigen Receives FDA Approval for Clinical Trial of AV201 II-42
• UK GTAC Approves Clinical Trial II-42
• CYGEE Bags patent Approval for Novel Gene Therapy Technology II-42
• Mirus Bio Receives $1.26 million SBIR Grant II-42
• CEGE Trials Novel Gene Therapy II-42
• Avigen Suspends Haemophilia Gene Therapy Trials II-43
• Oxford BioMedica and RPR Enters into Licensing Agreement II-43
• Schering AG Acquires Collateral Therapeutics II-43
• MolMed SpA Buys Rights to RectroNectin II-43
• Avigen Receives US FDA Approval II-43
• Transkaryotic Patent Case on Gene Therapy Settled II-44
• Targeted Genetics Receives Patents II-44
• Enzo Biochem Conducts Phase I Studies Related to HIV
• Treatment II-44
• Eurogene Acquires Oy Quattrogene II-44
• Cardion AG Acquires Tolerance Pharmaceuticals II-44
• Aventis Restructures Gene-Therapy Alliance with Introgen II-44
• Boehringer Ingelheim Austria GmbH Inks Agreement with BIA Separations II-44
• AVAX's Genopoietic Receives Contract from French Army II-45
• Cell Genesys Establishes New Subsidiary II-45
• Aventis Pharma Creates New Gencell Unit II-45
• Chiron Divests Gene Therapy Manufacturing Facility II-45
• ViroMed Conducts Clinical Trials on Gene Therapy Drug II-45
• EG009 Gene Therapy Doubles Survival Rate of Malignant
• Glioma Patients in Phase I/II Clinical Trials II-45
• Genteric Receives Patent for Insulin Gene Pill System II-46
• Bayer Corp. Receives Marketing and Distribution Rights to Coagulin-B II-46
• Avigen Receives Patent for Parkinson's Disease Gene Therapy II-46
• Genteric Receives US Patent for Gene Pill Method II-46
• Kimeragen Merges with ValiGene SA II-46
• Aventis Acquires License form Electrofect II-47
• DeveloGen Acquires Hepavec II-47
• Targeted Genetics Acquires Genovo Inc II-47
• GenStar Acquires Allegro Inc II-47
• Argonex and Rohm & Haas Company Enter into a Joint Venture II-47
• Nexell Therapeutics and Takara Shuzo Join Forces II-47
• BTG International Inks Licensing Agreement with Avigen Inc II-48
• Oxford BioMedica Awarded US Patens Concerning Retroviral And Lentiviral Systems II-48
• Genteric Receives Gene Therapy Patent II-48
• GenVec Granted Broad Gene Therapy Patent II-48

11. Focus on Key Players II-49

• AnGes MG Inc (Japan) II-49
• Athersys Inc (US) II-49
• Avigen (US) II-50
• Canji Inc (US) II-50
• Cell Genesys II-50
• Centelion SA (France) II-50
• GenVec (US) II-51
• Genzyme Corporation (US) II-51
• Introgen Therapeutics Inc (US) II-51
• Oxford BioMedica (UK) II-52
• Shenzhen SiBiono GeneTech Co., Ltd (China) II-52
• Targeted Genetics Corp (US) II-52
• Transgene (France) II-53
• Valentis Inc. (US) II-53
• Vical (US) II-53

12. Global Market Perspective II-55

• Table 5: World Current & Future Market Analysis for Gene Therapy by Geographic Region - US, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2005 through 2010 (includes corresponding Graph/Chart) II-55
• Table 6: World 5-Year Perspective for Gene Therapy by Geographic Region - Percentage Breakdown of Dollar Sales for US, and Rest of World Markets for Years 2005 and 2010 (includes corresponding Graph/Chart) II-55

III. MARKET

1. The United States III-1

• A. Market Analysis III-1
• Regulatory Environment III-1
• Food and Drug Administration III-1
• IRB and IBC III-1
• OBA III-2
• NIH III-2
• Focus on Key Players III-2
• Athersys Inc III-2
• Avigen III-3
• Canji Inc III-3
• Cell Genesys III-3
• GenVec III-4
• Genzyme Corporation III-4
• Introgen Therapeutics Inc III-4
• Targeted Genetics Corp III-5
• Valentis Inc. III-5
• Vical III-5
• Strategic Developments III-6
• B. Market Analytics III-12
• Table 7: US Current & Future Market Analysis for Gene Therapy - Annual Sales Figures in US$ Million for Years 2006 through 2010 (includes corresponding Graph/Chart) III-12

2. Rest of World III-13

• A. Market Analysis III-13
• Review of Major Markets III-13
• Europe III-13
• Germany and UK- The Hub of European Gene Therapy Market III-13
• Table 8: Gene Therapy Clinical Trials in Europe (2004): Percentage Breakdown of Number of Trials by Country for UK, Germany, France, Belgium, Italy, Netherlands, and Others(includes corresponding Graph/Chart) III-13
• Regulatory Environment III-14
• Gene Therapy Advisory Committee III-14
• The European Society of Gene Therapy (ESGT) III-14
• Study of Regulatory Environment in Select European Countries III-15
• United Kingdom III-15
• Local Research Ethics Committee (LREC) III-15
• Medicines Control Agency III-15
• France III-15
• Germany III-16
• Italy III-16
• Austria III-16
• Sweden III-17
• The Netherlands III-17
• Belgium III-17
• Spain III-17
• Switzerland III-17
• Japan III-17
• Asia-Pacific III-18
• World's First Gene Therapy Medicine Approved in China III-18
• Prospects for Gendicine III-19
• Competition III-19
• Leading Gene Therapy Formulations under III-19
• Clinical Trials by Select Co., in China III-19
• Rest of World III-19
• Focus on Key Players III-19
• AnGes MG Inc (Japan) III-19
• Centelion SA (France) III-20
• Oxford BioMedica (UK) III-20
• Shenzhen SiBiono GeneTech Co., Ltd (China) III-20
• Transgene (France) III-21
• Strategic Developments III-21
• B. Market Analytics III-26
• Table 9: Rest of World Market for Gene Therapy - Current & Future Analysis by Annual Sales Figuresin US$ Million for Years 2005 through (includes corresponding Graph/Chart)2010 III-26

IV. COMPETITION

• 1. Affymetrix, Inc. (USA) IV-1
• Table 10: Half-Yearly Sales Analysis: 2004-2005 (H1) (In US$ million) IV-2
• Table 11: Annual Sales Analysis: 2003-2004 (In US$ million) IV-2
• 2. Aldevron LLC (USA) IV-6
• 3. AlphaVax, Inc. (USA) IV-8
• 4. Amaxa GmbH (Germany) IV-10
• 5. Amgen, Inc. (USA) IV-15
• Table 12: Half Yearly Sales Analysis: 2004-2005 (H1) (In US$ million) IV-16
• Table 13: Half Yearly Sales Analysis by Geographic Region: 2004-2005 (Q1) (In US$ million) IV-16
• Table 14: Annual Sales Analysis: 2003-2004 (In US$ million) IV-16
• Table 15: Annual Sales Analysis by Geographic Region: 2003-2004 (In US$ million) IV-16
• 6. AMT BV (The Netherlands) IV-19
• 7. AnGes MG, Inc. (Japan) IV-21
• 8. Antigenics, Inc. (USA) IV-25
• Table 16: Half-Yearly Sales Analysis: 2004-2005 (H1) (In US$ million) IV-25
• Table 17: Annual Sales Analysis: 2003-2004 (In US$ million) IV-26
• 9. Antisense Pharma GmbH (Germany) IV-28
• 10. Applied Genetic Technologies Corporation (USA) IV-29
• 11. Ariad Gene Therapeutics, Inc. (USA) IV-30
• 12. Ark Therapeutics Ltd. (UK) IV-31
• Ark Therapeutics OY (Finland) IV-32
• 13. Athersys, Inc. (USA) IV-34
• 14. Austrianova (Austria) IV-36
• 15. Automated Cell Technologies, Inc. (USA) IV-37
• 16. Avax Technologies, Inc. (USA) IV-38
• Table 18: Half Yearly Sales Analysis: 2004-2005 (H1) (In US$ thousand) IV-38
• Table 19: Annual Sales Analysis: 2004-2005 (In US$ thousand) IV-39
• 17. AVI Biopharma, Inc. (USA) IV-40
• 18. Avigen, Inc. (USA) IV-42
• Table 20: Half-Yearly Sales Analysis: 2004-2005 (H1) (In US$ million) IV-42
• Table 21: Annual Sales Analysis: 2003-2004 (In US$ million) IV-42
• Table 22: Quarterly Sales Analysis: 2003-2004 (In US $ million) IV-43
• 19. Bavarian Nordic A/S (Denmark) IV-45
• 20. Bionomics Limited (Australia) IV-48
• 21. Biophan Technologies, Inc. (USA) IV-49
• 22. Biophoenix (UK) IV-50
• 23. BioProtein Technologies (France) IV-51
• 24. Biosense Webster, Inc. (USA) IV-52
• 25. BioVex Ltd. (UK) IV-57
• 26. Celera Genomics Group (USA) IV-59
• 27. Cell Genesys, Inc. (USA) IV-62
• Table 23: Annual Sales Analysis: 2003-2004 (In US$ million) IV-63
• 28. Celltech Group PLC (UK) IV-67
• 29. Celsion Corporation (USA) IV-73
• 30. Centelion (France) IV-75
• 31. CereGene, Inc. (USA) IV-76
• 32. Cobra Biomanufacturing PLC (UK) IV-77
• 33. Copernicus Therapeutics, Inc. (USA) IV-79
• 34. Corixa Corporation (USA) IV-82
• Table 24: First Quarter Sales Analysis: 2004-2005 (Q1) (In US$ million) IV-82
• Table 25: Annual Sales Analysis: 2003-2004 (In US$ million) IV-83
• 35. Cosmo SpA (Italy) IV-87
• Cosmo Bioscience, Inc. (USA) IV-88
• 36. Crucell NV (The Netherlands) IV-90
• 37. Cyclacel Limited (UK) IV-94
• 38. Cygene Laboratories (USA) IV-96
• 39. Cytogen Corporation (USA) IV-97
• Table 26: Half Yearly Sales Analysis: 2004-2005 (H1) (In US$ million) IV-97
• Table 27: Half Yearly Sales Analysis By Product: 2004-2005 (H1) (In US$ million) IV-98
• Table 28: Annual Sales Analysis: 2003-2004 (In US$ million) IV-98
• Table 29: Annual Sales Analysis By Product: 2003-2004 (In US$ million) IV-98
• 40. CytRx Corporation (USA) IV-100
• 41. DeveloGen AG (Germany) IV-103
• 42. Diversa Corporation (USA) IV-105
• 43. Enzo Biochem, Inc. (USA) IV-109
• 44. Fit Biotech Oyj PLC (Finland) IV-111
• 45. Gene Therapy Systems, Inc. (USA) IV-112
• 46. GeneCure LLC (USA) IV-119
• 47. GenEra SpA (Italy) IV-120
• 48. Genetix Pharmaceuticals, Inc. (USA) IV-121
• 49. Genteric, Inc. (USA) IV-122
• 50. GenVec, Inc. (USA) IV-124
• Table 30: Half Yearly Sales Analysis: 2004-2005 (In US$ million) IV-125
• 51. Genzyme Corporation (USA) IV-129
• Table 31: Half Yearly Sales Analysis: 2004-2005 (H1) (In US$ million) IV-131
• Table 32: Annual Sales Analysis: 2003-2004 (In US$ million) IV-131
• Table 33: Annual Sales Analysis by Segment: 2003-2004 (In US$ million) IV-132
• Table 34: Annual Sales Analysis by Geographical Region: 2003-2004 (In US$ million) IV-132
• Genzyme Molecular Oncology (USA) IV-138
• Genzyme Therapeutics (UK) IV-139
• 52. Geron Corporation (USA) IV-140
• Table 35: First Half Sales Analysis:
• 2004-2005 (H1) (In US$ million) IV-140
• Table 36: Annual Sales Analysis: 2003-2004 (In US$ million) IV-141
• Table 37: Quarterly Sales Analysis: 2003-2004 (In US$ million) IV-141
• 53. Gilead Sciences, Inc. (USA) IV-143
• 54. Glygen Corporation (USA) IV-147
• 55. GTx, Inc. (USA) IV-149
• 56. Guidant Corporation (USA) IV-152
• Table 38: Half-Yearly Sales Analysis by Quarters: 2004-2005 (H1) (In US$ million) IV-153
• Table 39: Half-Yearly Sales Analysis by Product: 2004-2005 (H1) (In US$ million) IV-153
• Table 40: Half-Yearly Sales Analysis by Geographic Region: 2004-2005 (H1) (In US$ million) IV-153
• Table 41: Annual Sales Analysis: 2003-2004 (In US$ million) IV-153
• Table 42: Annual Sales Analysis By Product: 2003-2004 (In US$ Million) IV-153
• Table 43: Annual Sales Analysis By Geographic Region: 2003-2004 (In US$ million) IV-154
• 57. Human Genome Sciences, Inc. (USA) IV-159
• Table 44: Half Yearly Sales Analysis: 2004-2005 (In US$ million) IV-160
• Table 45: Annual Sales Analysis: 2003-2004 (In US$ million) IV-160
• Table 46: Annual Sales Analysis by Quarters: 2003-2004 (In US$ million) IV-160
• 58. ImGenex Corporation (USA) IV-164
• 59. Immusol, Inc. (USA) IV-172
• 60. Innovata Plc (U K) IV-175
• 61. Introgen Therapeutics, Inc. (USA) IV-176
• 62. Intronn LLC (USA) IV-180
• 63. Invitrogen Corporation (USA) IV-182
• Table 47: Half Yearly Sales Analysis: 2004-2005 (H1) (In US$ million) IV-184
• Table 48: Annual Sales Analysis: 2003-2004 (In US$ million) IV-184
• Table 49: Annual Sales Analysis by Segment: 2003-2004 (In US$ million) IV-184
• 64. InvivoGen (USA) IV-196
• 65. MaxCyte (USA) IV-203
• 66. Merck KGAA (Germany) IV-205
• Table 50: Half Yearly Sales Analysis by Quarter: 2004-2005 (In € million) IV-207
• Table 51: Annual Sales Analysis: 2003-2004 (In € million) IV-207
• 67. Mitsubishi Chemical Corporation (Japan) IV-210
• Table 52: Annual Sales Analysis: 2003-2004 (In ¥ billion) IV-211
• Table 53: Annual Sales Analysis By Segment: 2003-2004 (In ¥ billion) IV-212
• 68. MolMed SpA (Italy) IV-217
• 69. Northwest Biotherapeutics, Inc. (USA) IV-219
• 70. Novartis AG (Switzerland) IV-221
• Table 54: Half Yearly Sales Analysis: 2004-2005 (H1) (In US$ billion) IV-224
• Table 55: Annual Sales Analysis: 2003-2004 (In US$ billion) IV-224
• Table 56: Annual Sales Analysis by Division: 2003-2004 (In US$ billion) IV-225
• Table 57: Annual Sales Analysis by Geographical Region: 2003-2004 (In US$ billion) IV-225
• Table 58: Quarterly Sales Analysis: 2003-2004 (In US$ billion) IV-225
• 71. NsGENE A/S (Denmark) IV-232
• 72. Onyx Pharmaceuticals, Inc. (USA) IV-235
• 73. OSI Pharmaceuticals, Inc. (USA) IV-236
• Table 59: Half Yearly Sales Analysis: 2004-2005 (In US$ million) IV-236
• Table 60: Annual Sales Analysis: 2003-2004 (In US$ million) IV-237
• 74. Osiris Therapeutics, Inc. (USA) IV-240
• 75. Oxford BioMedica PLC (UK) IV-242
• 76. Oxxon Therapeutics Ltd. (UK) IV-244
• 77. Qugen Therapeutics Pte., Ltd. (Singapore) IV-246
• 78. RheoGene, Inc. (USA) IV-248
• 79. Sanofi-Aventis (France) IV-251
• Table 61: Half Yearly Sales Analysis: 2004-2005 (H1) (In € million) IV-252
• Table 62: Half Yearly Sales Analysis by Segment: 2004-2005 (H1) (In € million) IV-252
• Table 63: Half Yearly Sales Analysis by Product: 2004-2005 (H1) (In € million) IV-253
• Sanofi Aventis Pharmaceuticals, Inc. (USA) IV-256
• 80. Schering AG (Germany) IV-260
• Berlex Laboratories, Inc. (USA) IV-263
• Collateral Therapeutics, Inc. (USA) IV-267
• 81. Schering-Plough Corporation (USA) IV-269
• Table 64: First Quarter Sales Analysis by Segment: 2004-2005 (Q1) (US$ million) IV-270
• Table 65: First Quarter Sales Analysis by Regions: 2004-2005 (Q1) (US$ million) IV-270
• Table 66: Annual Sales Analysis by Segments: 2003-2004 (US$ million) IV-270
• Table 67: Annual Sales Analysis by Regions: 2003-2004 (US$ million) IV-270
• Canji, Inc. (USA) IV-274
• 82. Selective Genetics (USA) IV-275
• 83. Shanghai Sunway Biotech Co., Ltd. (China) IV-276
• 84. Shenzhen Sibiono Genetech Co., Ltd. (China) IV-277
• 85. Shire Pharmaceuticals Group PLC (UK) IV-278
• Table 68: Half Yearly Sales Analysis: 2004-2005 (H1) (In US$ million) IV-279
• Table 69: Annual Sales Analysis: 2003-2004 (In US$ million) IV-279
• Table 70: Annual Sales Analysis by Product: 2003-2004 (In US$ million) IV-279
• 86. Sirna Therapeutics, Inc. (USA) IV-282
• 87. Stemcells, Inc. (USA) IV-284
• Table 71: Half Yearly Sales Analysis: 2004-2005 (H1) (In US$ thousand) IV-285
• Table 72: Annual Sales Analysis: 2003-2004 (In US$ thousand) IV-285
• 88. Supratek Pharma, Inc. (Canada) IV-286
• 89. Targeted Genetics Corporation (USA) IV-289
• Table 73: Half-Yearly Sales Analysis: 2004-2005 (H1) (In US$ million) IV-290
• Table 74: Annual Sales Analysis: 2003-2004 (In US$ million) IV-290
• 90. Theratechnologies, Inc. (Canada) IV-292
• Table 75: Half Yearly Sales Comparison: 2004-2005 (H1) (In C$ million) IV-293
• Table 76: Annual Sales Comparison: 2003-2004 (In C$ million) IV-293
• 91. Tosk, Inc. (USA) IV-295
• 92. TransGene SA (France) IV-296
• Table 77: First Half Yearly Sales Analysis: 2004-2005 (H1) (In € thousands) IV-297
• Table 78: Annual Sales Analysis 2003-2004 (In € thousands) IV-297
• TransGene, Inc. (USA) IV-298
• 93. Upstate Group, Inc. (USA) IV-299
• 94. Valentis, Inc. (USA) IV-305
• Table 79: Annual Sales Comparison: 2004-2005 (In US$ million) IV-305
• Table 80: Quarterly Sales Comparison: 2004-2005 (In US$ million) IV-306
• 95. Vical, Inc. (USA) IV-308
• Table 81: Half Yearly Sales Analysis: 2004-2005 (H1) (In US$ million) IV-309
• Table 82: Quarterly Sales Analysis: 2003-2004 (In US$ million) IV-309
• Table 83: Annual Sales Analysis: 2003-2004 (In US$ million) IV-309
• 96. VirRx, Inc. (USA) IV-313
• 97. VIRxSYS Corporation (USA) IV-313
• 98. Wyeth (USA) IV-314